<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	[data-slide='12'] > h2 { margin-bottom:12px; }
	.cols { height:384px; margin-top:45px; }
	.cols > li, .diagnosis > li, .brcam > li { font-size:16px; line-height:18px; }
	.cols > li { float:left; width:174px; height:inherit; text-align:center; font-family:interstatebold-condensed; border-right:1px dashed #004d74; }
	.cols > li:nth-child(2) { width:372px; }
	.cols > li:last-child { width:395px; }
	.cols > li span { display:block; color:#b2d234; font-size:20px; line-height:24px; margin-top:-30px; }
	div[class^=diagnosis] { height:80px; text-align:left; padding-left:45px; border-top:2px solid #bbbdbf; position:relative; opacity:0.25; }
	div[class^=diagnosis-1] { margin-top:32px; }
	div[class^=diagnosis-2], div[class^=diagnosis-1].active { border-bottom: 2px solid #bbbdbf; }
	div[class^=diagnosis-1].active + div[class^=diagnosis-2] { border-top:none; }
	div[class^=diagnosis-].active { opacity:1; }
	div[class^=diagnosis-]:before, div[class^=diagnosis-]:after { position:absolute; top:0; bottom:0; margin:auto 0; }
	div[class^=diagnosis-]:after { content:""; left:5px; width:32px; height:80px; background: url(img/woman2.png) 0 center no-repeat; background-size:100% auto; }
	div[class^=diagnosis-]:before { content:"\e603"; color:#bbbdbf; font-size:32px; height:30px; right:0; transform:rotate(-90deg); }
	.cols div i, .diagnosis i, .brcam i { display:table-cell; vertical-align:middle; height:inherit; }
	.wrap, .diagnosis > li:nth-child(n+5), .diagnosis:before, .brcam:before, .brcam span { position:absolute; }
	.diagnosis { width:100%; position:relative; }
	.wrap { width:0; top:185px; left:174px; height: 400px; opacity:0; }
	.diagnosis, .diagnosis:before, .brcam, .brcam:before { height:inherit; }
	.diagnosis:before, .brcam:before { content:""; left:0; background-repeat:no-repeat; background-size:100% auto; z-index:-1; }
	.diagnosis:before { width:614px; top:68px; background-image:url(img/chart.svg); }
	.diagnosis > li, .brcam > li { float:left; background-color:#004d74; color:#ffffff; font-family:interstateregular-condensed; text-align:center; }
	.diagnosis > li { width:131px; height:112px; padding:5px 10px; background-color:#004d74; color:#ffffff; font-family:interstateregular-condensed; text-align:center; opacity:0; }
	.diagnosis > li:first-child { width:50px; height:36px; margin:112px 7px 0; }
	.diagnosis > li:nth-child(3) { margin-right:25px; margin-left:25px; }
	.diagnosis > li:nth-child(2), 
	.diagnosis > li:nth-child(3),
	.diagnosis > li:nth-child(4) { margin-top:75px; }
	.diagnosis > li:nth-child(n+5) { margin-right:0; right:7px; top:2px; height:108px; }
	.diagnosis > li:nth-child(5) { background-color:#b2d234; height: 125px }
	.diagnosis > li:nth-child(6) { top:143px; }
	.diagnosis > li:last-child, .diagnosis > li:nth-child(7) { top:267px;  }
	.diagnosis > li:last-child { right:183px;  }
	.diagnosis > li:last-child:after { content:""; width:10px; height:20px; position:absolute; left:-66px; background-color:#fff; bottom: -2px;  }
	.diagnosis i { width:inherit; }
	.brcam { width:782px; margin-left: 33px; }
	.brcam > li { padding:10px; width:90px; height:162px; position:relative; top: 45px; text-align:center; margin-right:12px; }
	.brcam > li:first-child{ width:120px; }
	.brcam > li:nth-child(5) { margin-right:8px; }
	.brcam > li:last-child{ margin-right:0; }
	.brcam > li:nth-child(2), .brcam > li:nth-child(4) { width:82px; }
	.brcam li > span { width:25px; height:25px; left:0; right:0; margin:0 auto; bottom:-40px; font-family:interstatelight; font-size:23px; line-height:28px; }
	.brcam i { width:inherit; }
	.brcam:before { width:inherit; top:0; background-image:url(img/chart2.svg); background-position:-12px 130px; }
	
	.capsule { width:944px; height:640px; left:0; bottom:0; background:#ffffff; padding:22px 40px; box-shadow:0 0 20px rgba(0, 0, 0, 0.5); }
	.capsule > div { width:400px; position:relative; }
	.capsule .list li { font-size:16px; line-height:21px; }
	.capsule .close { right:40px; top:28px; }
	.list + p { font-family:interstatebold; margin-top:10px; }
	.intro { display:block; padding:15px; margin-top:40px; font-family:interstateregular; font-size:19px; line-height:23px; background-color:rgba(0, 77, 116, 0.15); }
	.capsule .footnote, .capsule > div:after { position:absolute; }
	.capsule .footnote { right:-130px; bottom:-3px; font-family:interstatelightCon; }
	.capsule > div:after { content:""; width:372px; height:500px; top:0; right:-470px; background:url(img/oral_tga_diagram.png) 0 8px no-repeat; background-size:100% auto; }
	
	/* 13 */
	[data-slide='13'] > h2 { letter-spacing:-0.02em; margin-bottom:40px; }
	.circular { width:615px; height:270px; background:url(img/circular.svg) 0 0 no-repeat; background-size:100% auto; position:relative; top:-12px; }
	.circular:before { content:"BRCAm"; font-size:26px; font-family:interstateregular; position:absolute; top:130px; right:190px; letter-spacing:-0.04em; }
	.circular > .btn-play.graph { left:auto; right:100px; top:100px; }
	.indicator { overflow:hidden; margin-bottom: 15px; }
	.indicator > li, .woman > li { float:left; }
	.indicator > li, .mute { font-size:22px; line-height:25px;  }
	.indicator > li { width:300px; margin-right:30px; }
	.indicator > li:last-child { width:280px; margin-right:0; }
	.indicator > li:last-child .a { opacity:0; }
	.indicator li:nth-child(n+2) { display:none; }
	.indicator > li i { font-size:14px; position:relative; bottom:-5px; letter-spacing:-0.015em; }
	.indicator .percent { font-family:interstatebold;  display:block; font-size:78px; line-height:78px; letter-spacing:-0.04em; }
	.indicator li > .btn-result { display:block; width:200px; margin:0 auto; text-align:center; background-color:#004d74; color:#ffffff; padding:10px 0; font-size:inherit; line-height:24px; font-family:interstatebold; letter-spacing:-0.04em; }
	.content li p { letter-spacing:-0.022em; }
	.progress { width:84%; height:10px; position:relative; background:rgba(0, 77, 116, 0.15); }
	.progress > span { width:0%; position:absolute; top:0; left:0; height:inherit; background-color:rgba(0, 77, 116, 0.95); }
	.woman { width:860px; height:153px; margin:0 0 3em 2.5em; display:none;  }
	[data-slide='13'] .woman { opacity:0; }
	.woman > li { width:70px; height:inherit; margin-right:17px; background-image: url(img/woman.png); background-repeat:no-repeat; background-color:#004d74; background-size:100% auto; position:relative; opacity:0.15; }
	.woman + p { letter-spacing:-0.015em; }
	.woman > .active { opacity:1; }
	.mutation .indicator > li:last-child { opacity:0.16; }
	.mutation .woman > li:first-child, 
	.mutation .woman > li:nth-child(5) { background-color:transparent; background-image:url(img/mutation_figure.png); }
	.mutation .woman > li:first-child:before, 
	.mutation .woman > li:nth-child(5):before { opacity:0.7; }
	.woman > li:last-child { margin-right:0; }
	.woman > li:before { content:""; position:absolute; width:60px; height:6px; left:0; right:0; margin:0 auto; bottom:-3px; border-radius: 30px / 3px; background:radial-gradient(ellipse at center, rgba(0, 77, 116,1) 5%,rgba(0, 77, 116,1) 14%, rgba(0, 77, 116, 0) 100%); }
	.mute { opacity:0; }
	.woman > .grad:after { content:""; position:absolute; width:inherit; height:110%; left:100%; top:0; 
	background: -webkit-linear-gradient(left, rgba(255, 255, 255, 0), rgba(255, 255, 255, 0.9)); 
	background: linear-gradient(left, rgba(255, 255, 255, 0), rgba(255, 255, 255, 0.9));  }
	.woman > .grad.active:after { left:15%; }
	
	/*.state_1 .circular { display:none; }*/
	
	/* 14 */
	[data-slide='14'] > h2 { letter-spacing:-0.02em; margin-bottom:45px; }
	.quote { width:672px;  font-size:50px; line-height:55px; margin: 0 auto; padding-bottom:20px; }
	.quote + span { display:block; font-size:19px; line-height:22px; margin-left:155px; }
	
	/* 15 */
	[data-slide='15'] > h2 { letter-spacing:-0.02em; margin-bottom:55px; }
	[data-slide='15'] p { font-size:22px; line-height:28px; }
	[data-slide='15'] .percent { font-family:interstatebold; font-size:75px; line-height:91px; margin: 25px 0 12px }
	[data-slide='15'] .woman { display:block; width:100%; margin:0; height:88px; margin-bottom:32px; }
	[data-slide='15'] .woman li { width:40px; height:inherit; margin-right:7px; }
	[data-slide='15'] .woman li:last-child { margin-right:0; }
	[data-slide='15'] .woman > li:before { width:40px; height:4px; left:0; right:0; margin:0 auto; bottom:-2px; border-radius: 20px / 2px; background:radial-gradient(ellipse at center, rgba(0, 77, 116,1) 5%,rgba(0, 77, 116,1) 14%, rgba(0, 77, 116, 0) 100%); }
	
	.btn-capsule { background-image:url(img/HGSO_icon.png); }
	.slim { position:absolute; bottom:14px; left:55px; margin-bottom:0; }
	.slim > span { display:none; }
	.slim.tall > span { display:block; }
	.slim.tall { bottom:2px; }
	.footnote { min-width:490px; opacity:0; }
	.indicator > li, .indicator .percent, .progress > span, .woman > li, .woman > .grad:after, .mute { -webkit-transition:all 0.5s ease-in-out; transition:all 0.5s ease-in-out; }
	
</style> 
</head>
<body>
	<section id="container">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <div class="swiper-container">
                <ul class="swiper-wrapper">
                	<!-- slide 4-->
                    <li class="swiper-slide" data-slide="12">
                         <h2><span>BRCAm TESTING</span>
                            PATIENTS WITH HGSOC ARE ELIGIBLE FOR TREATMENT WITH
LYNPARZA IF THEY HAVE A CONFIRMED BRCA MUTATION<sup data-ref="4">4</sup>
                        </h2>
                        <p>Standard of care following completion of platinum-sensitive relapsed high grade serous ovarian cancer therapy
is commonly ‘watch and wait’ (no active therapy).<sup data-ref="6">6</sup></p>
            
                        <ul class="cols">
                        	<li class="icon"><span>Diagnosis</span>
                            	<div class="diagnosis-1 active"><i>Ovarian Cancer<br />
Patient<br />
Journey</i></div>
                            	<div class="diagnosis-2 active"><i>Ovarian Cancer<br />
BRCA Mutation<br />
Testing Program</i></div>
                            </li>
                        	<li><span>First relapse</span></li>
                        	<li><span>Second and subsequent relapse</span></li>
                        </ul>
                        <div class="wrap">
                        	<ul class="diagnosis hide">
                        		<li><i>Test for
BRCAm</i></li>
                        		<li><i>Initial treatment:<br />
surgery +/-<br />
platinum-based<br />
chemotherapy</i></li>
                        		<li><i>Surveillance<br />
(watch & wait)</i></li>
                        		<li><i>Platinum-sensitive<br />
relapsed patients†:<br />
platinum-based<br />
chemotherapy</i></li>
                        		<li><i>BRCAm<br />
platinum-sensitive<br />
relapsed patients<br />
are eligible<br />
for maintenance<br />
treatment with<br />
Lynparza*</i></li>
                        		<li><i>Wild type BRCA<br />
patients: surveilance<br />
(watch & wait)</i></li>
                        		<li><i>Surveillance<br />
(watch & wait)</i></li>
                        		<li><i>Platinum-refractory<br />
patients:<br />
chemotherapy</i></li>
                        	</ul>
                            <ul class="brcam hide">
                            	<li>
                                	<i>BRCAm<br />
platinum-sensetive<br />
relapsed high grade<br />
serous ovarian<br />
cancer relapsed<br />
patients are eligible<br />
for maintenance<br />
treatment with<br />
Lynparza</i>
                               	</li>
                            	<li data-info="12a">
                                	<i>Eligibility</i>
                                	<span class="btn btn-info sub">i</span>
                                </li>
                            	<li data-info="12b">
                                	<i>Pre-test<br />
genetic<br />
counselling<br />
hotline<br />
1800 770 735</i>
                                	<span class="btn btn-info sub">i</span>
                                </li>
                            	<li data-info="12c">
                                	<i>BRCA<br />
mutation<br />
analysis &<br />
results</i>
                                	<span class="btn btn-info sub">i</span>
                                </li>
                            	<li data-info="12d">
                                	<i>Post-test<br />
counselling<br />
for women<br />
with a<br />
BRCA1/2<br />
mutation</i>
                                	<span class="btn btn-info sub">i</span>
                                </li>
                            	<li data-info="12e">
                                	<i>PARPi<br />
eligibility for<br />
women with<br />
a BRCA 1/2<br />
mutation</i>
                                	<span class="btn btn-info sub">i</span>
                                </li>
                            </ul>
                        </div>
                        
                        
                        <div class="footnote slim">
                        	HGSOC=High Grade Serous Ovarian Cancer
                            <span>* Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive<br />
relapsed BRCA-mutated (germline and/or somantic) high grade serous epithelial ovarian, fallopian tube, or primary<br />
peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy<sup data-ref="4">.4</sup><br />
<sup>†</sup> Platinum-sensitive defined by a relapse-free period of <span class="sym">≥</span>6 months following a respose to the final dose of<br />
platinum-based chemotherapy treatment.</span>
                        </div>
                       
                    </li>
                    <!-- slide 13 -->
                    <li class="swiper-slide" data-slide="13">
                         <h2><span>ABOUT BRCAm</span>
                           ANY WOMAN WITH OVARIAN CANCER COULD HAVE A BRCA MUTATION<sup data-ref="13,14">13,14</sup>
                        </h2>
                       <ul class="indicator">
                            <li>
                            	<i>APPROXIMATELY</i>
                                <span class="percent">15%</span>
                               <p>of ovarian cancer patients have<br />
a BRCA mutation.<sup>15</sup></p>
                            </li>
                            <li>
                            	<div class="progress"><span></span></div>
                                <i class="a hide">APPROXIMATELY</i>
                                <span class="percent">0%</span>
                               <p class="q">What proportion of patients<br />
with BRCAm ovarian cancer<br />
do you believe have no relevant<br />
family history?</p>
<p class="a hide">of patients with BRCAm ovarian<br />
cancer may have no relevant<br />
family history.<sup data-ref="13,14">13,14</sup></p>
                            </li>
                            <li>
                            	<span class="btn-result">SUBMIT & SEE RESULTS</span>
                                <p class="a hide">
                                <i>OVER</i>
                                <span class="percent">70%</span>
                                of women are over 50 years<br />
old at diagnosis.<sup data-ref="16">16</sup>
                                </p>
                            </li>
                       </ul>
                       <ul class="woman">
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                       </ul>
                       <div class="circular"><span class="btn btn-play graph"></span></div>
                       <p class="mute">Restricting genetic testing to older patients, those with a family history or certain ethnic groups<br />
<strong>may mean that some women with BRCA mutations are missed.</strong><sup data-ref="17">17</sup></p>
						
                    </li>
                     <!-- slide 14 -->
                    <li class="swiper-slide" data-slide="14">
                         <h2><span>TESTING GUIDELINES</span>
                           RESTRICTING GENETIC TESTING BY AGE OR FAMILY HISTORY, MAY MEAN
WOMEN WITH BRCAm ARE MISSED<sup data-ref="17">17</sup>
                        </h2>
                        <p class="quote">“Women diagnosed with<br />
&nbsp; epithelial ovarian, tubal, and<br />
&nbsp; peritoneal cancers should<br />
&nbsp; receive genetic counseling<br />
&nbsp; <strong>and be offered genetic<br />
&nbsp; testing, even in the absence<br />
&nbsp; of a family history.”<sup data-ref="18">18</sup></strong></p>
<span>- Society of Gynecologic Oncology, October 2014</span>
                        
                   	</li>
                     <!-- slide 15 -->
                    <li class="swiper-slide" data-slide="15">
                         <h2><span>BRCAm STATUS</span>
                           BRCAm STATUS IS CRITICAL FOR THE IDENTIFICATION OF PATIENTS
WITH OVARIAN CANCER SUITABLE FOR LYNPARZA<sup data-ref="4">4</sup>
                        </h2>
                        <p>Limited information on the incidence of BRCAm in the platinum-sensitive relapsed<br />
setting is available. Combined data from <strong>two individual studies</strong> suggest that about:</p>
<p class="percent">30-40% patients</p>
<ul class="woman">
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
	<li></li>
</ul>
<p>of patients with platinum-sensitive relapsed ovarian cancer are considered<br />
to possibly have BRCAm disease.<sup data-ref="3,13">3,13</sup></p>
                    </li>
                </ul><!-- end swiper-wrapper -->
                <!-- Add Arrows -->
       			<span class="swiper-button icon arrow swiper-button-next"></span>
        		<span class="swiper-button icon arrow swiper-button-prev"></span>
            </div>
            
        	<span class="logo lynp"></span>
            <span class="btn btn-info hide">i</span>
            <span class="btn btn-capsule"></span>
        </article>
    
    <!-- popup -->
    <div class="overlay shade">
    	<!-- reference -->
    	<div class="ref hide">
            <div class="item"> <span class="close icon"></span>
                <h1>References</h1>
                <ol></ol>
            </div>
        </div><!-- end ref -->
         <!-- info -->
        <div class="item info hide"><span class="arrow icon"></span>
            <!-- 12 -->
             <ul class="list hide" data-info="12a">
                <li>Diagnosis of high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer</li>
                <li>Unknown BRCA 1/2 mutation status</li>
                <li>At first or subsequent relapse</li>
                <li>At any age</li>
                <li>Irrespective of family history</li>
            </ul>
            <div data-info="12b" class="hide">
            	<p>During the patient consultation:</p>
                <ol>
                   
                    <li>Contact the genetic counselling hotline on 1800 770 735 to arrange a pre-test, telephone based<br />
        genetic counselling appointment.</li>
                    <li>Genetic counselling service provides patient with a testing kit containing the required documentation<br />
        and collection materials.</li>
                    <li>Patient attends local pathology service for blood collection and kit is sent to testing laboratory<br />
        in supplied pre-paid self-addressed satchel.</li>
                </ol>
           </div>
           <div class="hide" data-info="12c">
           		<p>BRCA mutation testing results and interpretation are sent to the referring clinician and also sent<br />
to PMCC genetic counselling service.</p>
             <ul class="list" >
                <li>National availability</li>
				<li>4-week turnaround time</li>
            </ul> 
           </div>
           <div class="hide" data-info="12d">
           		Women tested positive for germline BRCA1/2 mutation (pathogenic, likely pathogenic or VUS) and
patients with a significant family history will be assisted in accessing face-to-face post-testing genetic
counselling. Payment for post-test genetic counselling is not included in the program.
           </div>
            <div class="" data-info="12e">
           		Identification of a BRCA mutation may inform treatment options, including eligibility for a PARP inhibitor<br />
access program supported by AstraZeneca.
           </div>
            <div class="" data-info="14">
            	Ovarian cancer guidelines still vary and usually stipulate only high risk patients (for example, family history, age, etc.) be identified and recommended for BRCA testing. However, this is changing and some guidelines, such as the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Breast and Ovarian, have been updated to recommend BRCA testing for all ovarian cancer patients.<sup data-ref="19">19</sup>
            
            </div>
            
        </div><!-- end info -->
        <div class="capsule"><span class="close icon"></span>
        	<h2>LYNPARZA is the only oral TGA approved maintenance<br />
therapy for BRCAm platinum-sensitive relapsed high-grade<br />
serous ovarian cancer patients<sup data-ref="4">4</sup></h2>
			<div>
			<ul class="list">
				<li>The recommended dose of Lynparza is 400 mg<br />
(eight 50mg capsules) taken twice daily, equivalent<br />
to a total daily dose of 800 mg.<sup data-ref="4">4</sup></li>
				<li>Patients should start treatment with Lynparza<br />
no later than 8 weeks after completion of their<br />
final dose of the platinum containing regimen.<sup data-ref="4">4</sup></li>
				<li>It is recommended that treatment be continued<br />
until progression of the underlying disease. There<br />
are no data to support retreatment with Lynparza<br />
as maintenance following subsequent relapse.<sup data-ref="4">4</sup></li>	
            </ul>
            <p>MISSING DOSE</p>
            <ul class="list">
                <li>If a patient misses a dose of Lynparza, they should<br />
take their next normal dose at its scheduled time.</li>
			</ul>
            <span class="intro">
            	LYNPARZA GIVES WOMEN WITH BRCAM<br />
PLATINUM-SENSITIVE RELAPSED<br />
HIGH-GRADE SEROUS OVARIAN CANCER<br />
THE OPPORTUNITY TO DELAY DISEASE<br />
PROGRESSION WITH THE CONVENIENCE<br />
OF AT HOME ADMINISTRATION.<sup data-ref="4">4</sup>
            </span>
            <span class="footnote">Adapted from Ledermann.<sup data-ref="3">3</sup></span>
            </div>
        </div>
      
       <!-- navigation -->
        <div class="item nav hide"><span class="close icon"></span>
        	<ul class="section">
        		<li data-href="1"><span>Unmet need</span></li>
        		<li data-href="2"><span>Mechanism<br />of action</span>
                	<ul>
                		<li data-href="2"><span>PARPi</span></li>
                		<li data-href="3"><span>DNA repair</span></li>
                	</ul>
                </li>
        		<li data-href="4"><span>Clinical Data</span>
                	<ul>
                		<li data-href="4"><span>Extended PFS</span></li>
                		<li data-href="5"><span>Study overview</span></li>
                		<li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                		<li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                		<li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                		<li data-href="9"><span>Overall Survival</span></li>
                		<li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                		<li data-href="11"><span>Patient Characteristics</span></li>
                	</ul>
                </li>
        		<li data-href="12"><span>BRCAm+</span>
                	<ul>
                		<li data-href="12"><span>BRCAm testing</span></li>
                		<li data-href="13"><span>About BRCAm</span></li>
                		<li data-href="14"><span>Testing<br />guidelines</span></li>
                		<li data-href="15"><span>BRCAm status</span></li>
                	</ul>
                </li>
        		<li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="16"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="17"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="18"><span>Patient<br />Support Kit</span></li>
                		<li data-href="19"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="20"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="20"><span>Safety and<br />tolerability</span></li>
                		<li data-href="21"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="22"><span>Summary</span></li>
        	</ul>
            
        </div><!-- end nav -->
    </div>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TweenMax.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		var tl2 = new TimelineLite(),
			tl3 = new TimelineLite(),
			tl4 = new TimelineLite(),
			tl5 = new TimelineLite(),
			tl6 = new TimelineLite(),
			btn = $('.cols li:first-child > div'),
			wrap = $('[data-slide=12] .wrap'),
			patient = $('.diagnosis'),
			brcam = $('.brcam'),
			li = $('.diagnosis > li'),
			li2 = $('.brcam > li'),
			footnote = $('.footnote'),
			slide13 = $('[data-slide=13]'),
			play = $('[data-slide=13] .btn-play'),
			capsule = $('.btn-capsule'),
			info = $('.content > .btn-info'),
			circular = $('.circular'),
			woman = slide13.find('.woman'),
			fig = woman.find('li'),
			col1 = $('.indicator > li:first-child'),
			col2 = $('.indicator > li:nth-child(2)'),
			percent = col2.find('.percent'),
			progress = $('.progress > span'),
			col3 = $('.indicator > li:last-child'),
			result = col3.find('.btn-result'),
			txt = $('.mute'),
			woman2 = $('[data-slide=15] .woman');
			
		var mySwiper = new Swiper('.swiper-container', {
        	paginationClickable: true,
        	direction: 'vertical',
			nextButton: '.swiper-button-next',
        	prevButton: '.swiper-button-prev',
			onSlideChangeStart: function(e){
				tl.pause(0);
				tl2.pause(0);
				tl3.pause(0);
				tl4.pause(0);
				tl5.pause(0);
				tl6.pause(0);
				btn.addClass('active');
				fig.removeClass('active').parent().removeClass('lock');
				col2.hide().find('.q').show().parent().find('.a').hide();
				progress.css('width', '0%').parent().show();
				percent.text('0%');
				woman.hide();
				capsule.hide();
				info.hide();
				result.hide();
				txt.css('opacity', 0);
				slide13.removeClass('a70 mutation');
				woman2.find('li').removeClass('active');
				switch(e.activeIndex){
					case 0:
						capsule.show();
					break;
					case 1:
						circular.show();
					break;
					case 2:
						info.show();
					break;
					case 3:
						info.show();
						tl6.play();
					break;
				}
				//console.log(e.activeIndex);
				//e.slideTo(9);
			} 
		  });
		  
		tl.pause(true)
			.to(patient, 0.2, { display: 'block', ease: Power0.easeOut }, 'show' )
			.staggerTo(li, 0.4, { opacity:1, ease: Power0.easeOut }, 0.15, 'show' )
			.to(wrap, 0.7, { opacity:1, width:'770px', ease: Power0.easeOut }, -0.1 )
			.to(footnote, 0.3, { opacity:1, className: '+=tall'}, 'show' );
		tl2.pause(true)
			.to(brcam, 0.2, { display: 'block', ease: Power0.easeOut }, 'show' )
			.staggerTo(brcam, 0.4, { opacity:1, ease: Power0.easeOut }, 0.2, 'show' )
			.to(wrap, 0.8, { opacity:1, width:'770px', ease: Power0.easeOut }, -0.03 )
			.to(footnote, 0.3, { opacity:1, className: '-=tall', ease: Power0.easeOut}, 'show' );
			
		btn.on('tap', function(){
			var $this = $(this);
				btn.removeClass('active');
				$this.addClass('active');
				tl.pause(0);
				tl2.pause(0);
			if($this.hasClass('diagnosis-1')){
				tl.play();
			}else{
				tl2.play();
			}
		})
		
		tl3.pause(true)
			.to(col1, 0.4, { opacity: 0.16, ease: Power0.easeOut }, -0.5 )
			.to(col2, 0.35, { display: 'block', ease: Power0.easeOut }, 'feat', '-=0.5' )
			.to(woman, 0.5, { display: 'block', opacity:1, ease: Power0.easeOut }, 'feat' );
		tl4.pause(true)
			.to(col3, 0.35, { display: 'block' }, 'show' )
				.to(result, 0.35, { display: 'block' }, 'show' );
		tl5.pause(true)
			.to(col2, 0.25, { opacity: 0.16, ease: Power0.easeOut }, 'feat', '-=0.2' )
			.to(col3.find('.a'), 0.5, { display: 'block', opacity:1 }, 'feat')
			.staggerTo(woman.find('li:nth-child(5), li:nth-child(6), li:nth-child(7)'), 0.35, { className: '+=active' }, 0.15, '-=1')
		tl6.pause(true)
			.staggerTo(woman2.find('li:nth-last-child(n+14)'), 0.35, { className:'+=active', delay:0.5, ease: Power0.easeOut  }, 0.15)
			.to(woman2.find('li:nth-child(7)'), 0.5, { className:'+=grad', ease: Power0.easeOut } );
		
		
		//slide 1
		play.on('tap', function(){
			tl3.play();
			$(this).parent().hide();
		});
		fig.on('tap', function(){
			var $this = $(this),
				cent = ($this.index()+1)*10;
			//console.log($this.index());
			if(!$this.parent().hasClass('lock')){
				fig.removeClass('active');
				for(var i=0; i <= $this.index(); i++){
					fig.eq(i).addClass('active');
				}
				progress.css('width', cent+'%');
				percent.text(cent+'%');
				
				tl4.play();
			}else{
				
				if(slide13.hasClass('a70')){ slide13.addClass('mutation'); txt.css('opacity', 1); }
				slide13.addClass('a70')
				tl5.play();
			}
		});
		//slide13
		
		col3.on('tap', '.btn-result', function(){
			$(this).hide();
			col2.find('.q').hide().parent().find('.a').show();
			fig.removeClass('active');
			progress.css('width', '40%').parent().hide();
			percent.text('40%');
			woman.find('li:nth-last-child(n+7)').addClass('active').parent().addClass('lock');
			
		})
		  
		 mySwiper.slideTo(3);
		/* $('.indicator .arrow').on('tap', function(){ 
				$(this).toggleClass('less').prev('p').slideToggle();
		 })*/
		 hideButton(play);
		 function hideButton(t){
			t.addClass('hide');
			setTimeout( function(){ t.removeClass('hide'); }, 1000);
		}
		
	})

</script>
</body>
</html>
